Significant differences in baseline diversity and composition of the gut microbiome between responders and nonresponders to anti-PD-1 therapy in metastatic melanoma patients have been reported, with enrichment of the Ruminococcaceae family of the Clostridiales order in responders whereas the Prevotellaceae family of the Bacteroidales order was enriched in nonresponders [63]. The gene discussed is PDCD1; the disease is metastatic melanoma.